The androgen receptor (AR), a nuclear receptor superfamily transcription factor, plays a key
role in prostate cancer. AR signaling is the principal target for prostate cancer treatment, but
current androgen-deprivation therapies cannot completely abolish AR signaling because of
the heterogeneity of prostate cancers. Therefore, unraveling the mechanism of AR
reactivation in androgen-depleted conditions can identify effective prostate cancer
therapeutic targets. Increasing evidence indicates that AR activity is mediated by the …